{"entity":{"id":"nct05479812","kind":"trial","name":"Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1 trial of WTX-124 run by Werewolf Therapeutics, Inc., completed.","summary":"Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT05479812 by Werewolf Therapeutics, Inc., with 156 participants enrolled, started 2022-08-15. Conditions recorded: Metastatic Solid Tumor and Advanced Solid Tumor. Interventions recorded: WTX-124 and pembrolizumab.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05479812","url":"https://clinicaltrials.gov/study/NCT05479812"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["wtx-124"],"companies":["werewolf-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05479812","phase":"1","setting":"A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors","sponsor":"Werewolf Therapeutics, Inc.","enrolled":156,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05479812/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"wtx-124","kind":"drug","name":"WTX-124","route":"/drugs/wtx-124/"}],"company":[{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/"}]}}